Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd has submitted its 34th Annual Report for FY 2024-25 to BSE, sent electronically to shareholders and also uploaded on the company's website. The 34th Annual General Meeting is scheduled for Monday, September 29, 2025 at 3:30 PM via video conferencing. The AGM notice includes several important resolutions: adoption of audited financials, re-appointment of Mr. Praveen J. Bafna as Director (retiring by rotation), appointment of Ms. Sathya Venkatachalam as Independent Director for 5 years, and appointment of M/s HSPN & Associates LLP as Secretarial Auditor for 5 years (FY26–FY30). Other notable resolutions include raising the Executive Director Mr. Vimal D. Shah's remuneration cap to Rs. 24 Lakhs, increasing the company's borrowing limit to Rs. 20 Crores, authorizing sale/lease of company undertakings up to Rs. 10 Crores, and raising the Section 186 loan/investment ceiling to Rs. 10 Crores. During the year, two directors resigned (Ms. Susmita Mahapatra and Mr. Shaikh Amanullah) and two new directors were appointed. Company Secretary Priyanka Lohiya was also appointed in July 2024.
Shareholders will vote on resolutions that significantly expand management's financial flexibility, including higher borrowing power (Rs. 20 Cr), authority to dispose of assets up to Rs. 10 Cr, and larger investment/loan limits. The increase in Executive Director remuneration and changes to the board may be closely watched by minority shareholders given the company's small size.